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TO THE EDITOR
Alopecia areata (AA) is an organ-
specific autoimmune disease in which
T cells are directed against hair folli-
cles, causing a non-scarring alopecia
ranging from patchy AA to total scalp
(alopecia totalis (AT)), or scalp and
body hair loss (alopecia universalis
(AU)) (Gilhar and Kalish, 2006). Pre-
vious studies have shown that major
histocompatibility complex genes on
chromosome 6p21 encoding human
leukocyte antigens (HLAs) are major
determining loci for T-cell-mediated
diseases including AA (Nair et al.,
2000; Martinez-Mir et al., 2007). In
addition to HLA molecules, major
histocompatibility complex class I
chain-related gene A (MICA), a stress-
inducible antigen, is also associated
with several autoimmune diseases in-
cluding AA (Barahmani et al., 2006).
MICA is located about 46.5 kb centro-
meric to HLA-B, 1.2 Mb telomeric to the
HLA-D region with a distance between
HLA-DQB1 and DRB1 of about 65 kb
(Nair et al., 2000). Whether class I or II
HLA genes are more important for
susceptibility to AA is not yet known
and would have implications for the
pathogenesis as a CD8þ or CD4þ
T-cell-mediated disease.
We have previously reported that in
sporadic AA, HLA-DQB1*03(*0301-
*0305) alleles were present in 92% of
patients with AT/AU and in 80% of all
patients with AA. We also showed that
the frequency of the HLA-DRB1*1104
allele increased for all types of AA
((Welsh et al., 1994; Colombe et al.,
1995; Duvic et al., 1995; Price and
Colombe, 1996), whereas the frequen-
cies of HLA-DR52a (HLA-DRB3*0101)
and HLA-DQB1*06 alleles were nega-
tively associated (Duvic et al., 1991;
Welsh et al., 1994). These genes (HLA-
DQB1 and HLA-DR) were also found to
be linked to familial AA (de Andrade
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et al., 1999). Using these AA families,
we also reported a significant associa-
tion with haplotypes HLA-DQ1-DR6-
MICA*5.1 and HLA-DQB1*0201-DR3-
MICA*5.1 and AA (Barahmani et al.,
2006).
To confirm previous reports, we
analyzed DNA samples of sporadic
(non-familial) cases of AA in patients
with no affected family members. The
samples were obtained through the
National Alopecia Areata Registry
(NAAR), a large, centralized database
funded by the National Institute of
Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) (Duvic et al., 2003).
The study was conducted according to
the Declaration of Helsinki Principles.
Participants gave written informed con-
sent approved by the institution review
board to have blood samples drawn for
genotyping. These AA samples were
classified into one of two phenotypic
and clinical categories: (1) persistent
patchy AA (AAP) or (2) AT/AU, defined
as total scalp and scalp/body hair loss
lasting more than 1 year.
A total of 443 samples were success-
fully genotyped for 61 HLA-DRB, DQB,
and DQA alleles and five MICA alleles
using PCR and sequence-specific oligo-
nucleotide probe hybridization (http://
www.ihwg.org/tmanual/TMcontents.htm).
Ninety-nine patients had AAP, 163 had
AT/AU, 29 patients had AAT, and 152
were unrelated controls. The AAT
patients (transient AA o 1 year) were
not included owing to small numbers.
All subjects were American Caucasian.
w2 test was performed to analyze the
association of HLA class II and MICA
alleles with risk of AA severity pheno-
types. The Bonferroni correction for
multiple comparisons was performed.
The corrected a-level is 0.0004, equal
to 0.05 divided by the total number of
alleles (66) times two phenotypes (AAP
and AT/AU). If the P-value was
o0.0004, the allele was considered to
have a statistically significant associa-
tion with AA. If the P-value was
between 0.05 and 0.0004, the signifi-
cance was interpreted as tentative
(Table 1).
The results of our analyses con-
firmed the previously reported positive
association of HLA-DQB1*0301 with
AT/AU (Welsh et al., 1994; Colombe
et al., 1995; Price and Colombe, 1996).
Also HLA-DRB1*1104 was found
to be strongly associated with risk of
AT/AU (P¼ 0.000033) but AAP (P¼
0.013) was not significant, possibly
due to smaller sample size. The asso-
ciation of DRB1*1104 with risk of AT/
AU might be due to linkage disequili-
brium of this allele with DQB1*0301
allele (Welsh et al., 1994).
We also previously reported an
association of the HLA-DQB1*0201-
DR3-MICA*5.1 haplotype in patients
with all AA phenotypes (P¼ 0.009) and
with AAP (P¼0.008) in multiplex
families (Barahmani et al., 2006). In
this study, we observed a strong nega-
Table 1. Significant HLA class II and MICA association in persistent patchy AA, AT/AU, and overall AA versus
controls
AAP (n=99) AT/AU (n=163) Overall AA1 (n=291)
Controls
(n=152)
HLA
alleles
Frequency2
n, (%) P-value OR CI
Frequency
n, (%) P-value OR CI
Frequency
n, (%) P-value OR CI
Frequency
n, (%)
DRB1*0301 12, (12) 0.0323 0.44 0.21, 0.90 12, (7) 0.0000664 0.26 0.13, 0.51 27, (9) 0.0000834 0.33 0.19,0.57 36, (24)
DRB1*0701 31, (31) 0.0223 2.01 1.12, 3.64 42, (26) 0.136 — — 78, (27) 0.06 — — 28, (18)
DRB1*1101 16, (16) 0.063 2.25 1.01, 4.99 28, (18) 0.0183 2.4 1.18, 4.95 49, (17) 0.0093 2.36 1.21,4.60 12, (8)
DRB1*1104 13, (13) 0.0133 3.68 1.35, 10.03 31, (19) 0.0000334 5.71 2.31, 14.13 46, (16) 0.000144 4.57 1.90,11.0 6, (4)
DRB1*1501 16, (16) 0.0163 0.46 0.24, 0.87 32, (20) 0.0493 0.59 0.35, 0.98 55, (19) 0.0123 0.55 0.35,0.87 45, (30)
DRB*52b 38, (38) 0.099 — — 82, (50) 0.0000844 2.57 1.61, 4.10 131, (45) 0.00073 2.08 1.36, 3.16 43, (28)
DRB*53 59, (60) 0.053 — — 100, (61) 0.00963 1.81 1.16, 2.84 175, (60) 0.0093 1.2 1.16,2.56 71, (47)
DQA1*0102 32, (32) 0.143 — — 50, (31) 0.05 0.61 0.38, 0.97 94, (32) 0.05 0.66 0.44,0.98 64, (42)
DQA1*0501 44, (44) 0.238 — — 82, (31) 0.023 1.74 1.11, 2.72 136, (47) 0.055 — — 56, (37)
DQB1*0201 11, (11) 0.00153 0.32 0.15, 0.65 15, (9) 0.0000184 0.26 0.14, 0.49 31, (11) 0.00000644 0.30 0.18,0.50 43, (28)
DQB1*0202 27, (27) 0.000154 4.01 1.95, 8.24 34, (21) 0.00253 2.81 1.42, 5.58 65, (22) 0.00024 3.08 1.63,5.79 13, (9)
DQB1*0301 45, (45) 0.00453 2.18 1.28, 3.71 97, (60) 0.0000000164 3.85 2.40, 6.19 154, (53) 0.00000044 2.95 1.93,4.50 42, (28)
DQB1*0602 20, (20) 0.140 — — 30, (18) 0.0333 0.55 0.32, 0.94 58, (20) 0.0433 0.61 0.39,0.96 44, (29)
MICA*5.1 55, (56) 0.0303 0.54 0.32, 0.92 106, (65) 0.402 — — 183, (63) 0.17 — — 106, (70)
AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; CI, confidence interval; HLA, human leukocyte antigen; MICA, major histocompatibility
complex class I chain-related gene A; OR, odds ratio.
Corrected a-level: 0.0004=(0.05/(66*2)).
1Overall AA includes AAT, AAP, and AT/AU.
2Number of individuals with at least one copy of the allele.
30.0004 oP-valueo0.05.
4P-value o0.0004.
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tive association between the HLA-
DQB1*0201 allele and the AT/AU
phenotype. A decreased frequency of
this allele has also been reported in an
Italian population with rheumatoid
arthritis (Morozzi et al., 1995).
Another strong negative association
was observed between the frequency of
HLA-DRB1*0301 (formerly known as
HLA-Dw3) and risk of AT/AU. Previous
reports also have shown a protective
effect of the HLA-DRB1*0301 allele in
AA (Akar et al., 2002; Broniarczyk-Dyla
et al., 2002; Entz et al., 2006). Of
interest, the frequencies of both HLA-
DQB1*0201 and HLA-DRB1*0301
alleles were increased in patients with
diabetes mellitus type I, whereas the
frequency of the HLA-DQB1*0301
allele was decreased (Diaz et al.,
2003; Buc et al., 2006). These findings
may provide one explanation for the
protective role of AA in diabetes
mellitus type I in probands (Wang
et al., 1994).
Our results demonstrated a new
positive association of the HLA-
DQB1*0202 allele with risk of AAP.
This allele has been reported to have a
protective role in fibrocalculous pan-
creatic diabetes (Chowdhury et al.,
2002), but this is the first report on the
association of this allele with risk of AA.
Of interest, HLA-DQB1*0202 and *0201
alleles only differ by one single amino
acid in the membrane-proximal domain,
residue 135 and are found on different
haplotypes (Olerup et al., 1997).
This study did not confirm a negative
association between the HLA-DR52a
allele (DRB3*0101) (Duvic et al.,
1991), but we did find a positive
association of the HLA-DR52b
(DRB3*0202) allele with risk of AT/
AU. The association of both HLA-
DR52a and HLA-DR52b alleles with
autoimmune diseases were reported
previously: HLA-DR52a with Graves’
disease in a Jamaican population (Smi-
kie et al., 2001), and HLA-DR52b allele
with multiple sclerosis in Korean chil-
dren (Oh et al., 2004).
In this study, we found that after a
multiple comparison correction, the
frequencies of HLA-DRB1*0701, -DRB1*
1101, -DRB1*1501, -DR53, -DQA1*
0501, DQB1*0602, and MICA*5.1
were not considered to be significantly
associated with risk of AA (0.0004oP
o0.05). More studies are indicated to
confirm lack of association.
The overall findings in this study
support our hypothesis that the HLAs
class II are major susceptibility deter-
minants for AA and may be useful
in distinguishing among AA severity
phenotypes.
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TO THE EDITOR
Several studies have used evidence
evaluating genetic alterations (Curtin
et al., 2005) and anatomic location
(Whiteman et al., 2003) to support
theories that melanoma is a heteroge-
neous disease with differing etiologies.
Using data from the large-scale, popu-
lation-based Surveillance, Epidemiol-
ogy, and End Results Program (SEER)
of the National Cancer Institute, we
examined whether age-specific inci-
dence patterns separated by sex and
site would reveal distinct melanoma
subgroups.
Age, sex, and anatomic site were
abstracted for all microscopically con-
firmed, first invasive cutaneous mela-
nomas among non-Hispanic white
adults collected by the SEER 17 Registry
Program from 2000 to 2004. Incidence
rates, summarized across 5-year age
groups, were plotted by age at diagnosis
on a log-log scale, and age distribution
curves were created. Detailed materials
and methods are available in Supple-
mentary Materials and Methods.
After excluding 15 cases missing age
at diagnosis, 48,673 cases were avail-
able for analysis (Table 1). Fifty-six
percent of patients were male, and the
mean age at diagnosis was 57.0 years.
Forty-one percent of all melanomas
occurred among those 40–59 years of
age. However, the age-specific inci-
dence rate peaked among people aged
70–79 years, who had an incidence rate
5.9 times higher (95% confidence
intervals, 5.6–6.2) than those aged
20–29 years. The incidence rate ratio
for females compared to males was 0.7
(95% confidence intervals, 0.7–0.7).
Forty-three percent of melanomas were
located on the extremities, 34% on the
trunk, 12% on the face/ears, 7% on the
scalp/neck, and 4% at other/unclassi-
fied sites.
The age-specific incidence rate
curve and the age distribution for all
melanoma cases are shown in Figure 1.
Rates for all cases increased rapidly
until age 55–59, then continued to rise
at slower rates before beginning to
decline (Figure 1a). The age distribution
plot displayed a multimodal distribu-
tion, with distinct early-onset and late-
onset peak frequencies of melanoma
occurring at ages 54 and 74 years,
respectively (Figure 1b).
Melanomas demonstrated different
incidence patterns by anatomic site.
Age-specific incidence rates among
those with trunk melanoma generally
increased until age 55–59 years, then
plateaued and subsequently declined
(Figure 1c). The flattening of rates for
trunk melanoma occurred earlier and
was more extreme for females than for
males. The age distribution of trunk
melanoma was predominantly uni-
modal, with early-onset peak frequencies
occurring at age 54 for males and 44 for
females (Figure 1d). In contrast, age-
specific incidence rates among those
with face/ear melanoma increased shar-
ply throughout older age (Figure 1e).
The age distribution for face/ear mela-
noma was unimodal with late-onset
peaks at age 77 for males and at age
78 for females (Figure 1f). Incidence
rates for melanomas of the extremi-
ties, scalp/neck, and other/unclassified
sites demonstrated various mixtures of
these two patterns and did not show
unimodal distributions (data not
shown). These distinct patterns for trunk
and face/ear melanomas were main-
tained when the analysis was limited to
those classified as superficial spreading
melanoma and nodular melanoma his-
tological subtypes (Figure 2).
The multimodal distribution of in-
vasive melanoma might be explained,
in part, by divergent patterns for ana-
tomic site. Broken down by site, trunk
melanomas displayed an early-onset
peak of melanoma incidence, while
face/ear melanomas demonstrated a
late-onset incidence peak. Comparable
divergent incidence rate patterns have
been noted for breast cancer, and the
bend in age-specific rates near meno-
pause has been termed Clemmesen’s
hook (Clemmesen, 1948; Anderson
et al., 2005). Clemmesen’s hook on
the age-specific incidence rate curve
has been shown to correspond to the
dip between the bimodal peaks of the
age distribution plot (Anderson et al.,
1950). Our data suggest the existence of
a Clemmesen’s hook for melanoma.
Bulliard (2000) analyzed age-and
surface area-adjusted incidence rates
by anatomic site for the non-Maori
population of New Zealand using data
from 1968 to 1993 and found patterns
similar to ours. Elwood and GallagherAbbreviations: SEER, Surveillance, Epidemiology, and End Results
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